Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

31.60 -0.38 (-1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews
Via Benzinga
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Earnings Scheduled For February 25, 2025
Via Benzinga
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews
Via Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
NASDAQ:HRMY is not too expensive for the growth it is showing.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. 
Via Chartmill
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
Earnings Outlook For Harmony Biosciences
Via Benzinga
NASDAQ:HRMY, a growth stock which is not overvalued.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
Friday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Via Benzinga
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
From Harmony Biosciences
Via Business Wire
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals. 
Via Chartmill
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
Via Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
The company is focused on developing its pipeline of sleep and epilepsy drugs. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.